Graybill Bartz & Assoc Ltd. now owns 32,167 shares of the healthcare product maker's stock worth $1,360,000 after buying an additional 380 shares during the period. MA's holdings in Abbott Laboratories were worth $378,000 as of its most recent filing with the SEC.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. NY raised its stake in shares of Abbott Laboratories by 0.3% in the first quarter. Winfield Associates Inc. now owns 2,293 shares of the healthcare product maker's stock worth $102,000 after buying an additional 169 shares during the period. Cypress Capital Management LLC WY now owns 2,531 shares of the healthcare product maker's stock worth $112,000 after buying an additional 696 shares during the last quarter. Curbstone Financial Management Corp raised its stake in Abbott Laboratories by 57.5% in the first quarter. Cedar Hill Associates LLC now owns 14,261 shares of the healthcare product maker's stock valued at $548,000 after buying an additional 41 shares in the last quarter. Capital Investment Advisors LLC bought a new position in shares of Abbott Laboratories during the third quarter worth about $342,000.
On Monday, Abbott Laboratories (NYSE:ABT) stock opened its trade at $43.92 and after floating in a range of $43.90 to $44.23, settled at $44.04. With 5.83 million shares average volume, it will take short sellers 2 days to cover their ABT's short positions.
Elon Musk's cousin Rive, former SolarCity CEO, to leave Tesla
As Reuters correctly notes, "the sale came as investors anxious about the solar panel installer's debt-fueled growth". Rive said that the solar panel installer is "healthier" than it has ever been, and it is time for him to move on.
ABT stock's price is now -3.34% down from its 52-week high and +22.84% up from its 52-week low. Over the last quarter, insiders sold 52,692 shares of company stock worth $2,374,632.
On 4/27/2017 Roger Bird, Insider, sold 5,600 with an average share price of $43.82 per share and the total transaction amounting to $245,392.00.
While looking at the SMA values of Abbott Laboratories (ABT), the 200 simple moving average (SMA) is considered a key indicator by traders and market analysts for determining the overall long-term trend. The healthcare product maker reported $0.48 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.43 by $0.05. The lowest sales estimate is $6.58 billion and the highest is $6.67 billion. Abbott Laboratories had a net margin of 6.71% and a return on equity of 15.74%. The business's quarterly revenue was up 29.7% on a year-over-year basis. Relative volume is ratio between current volume and 3-month average value, intraday adjusted. The firm is expected to issue its next quarterly earnings results on Wednesday, July 19th. Stockholders of record on Friday, April 14th were paid a dividend of $0.265 per share. It has a dividend yield of 2.41%. The ex-dividend date of this dividend is Tuesday, April 11th. Abbott Laboratories's payout ratio is now 113.98%.
'Sensitive' India Needs to Look Beyond Rifts With China, Say Chinese Media
India has been expressing concern over the CPEC project which links China's Muslim dominated Xinjiang province to the Gwadar deep-sea port in Pakistan.
TRADEMARK VIOLATION WARNING: This report was published by BBNS and is the property of of BBNS. If you are reading this story on another domain, it was stolen and reposted in violation of United States & global copyright law. The correct version of this article can be viewed at https://transcriptdaily.com/2017/05/16/shelter-mutual-insurance-co-has-4535000-position-in-abbott-laboratories-abt-updated.html.
A number of research analysts have recently issued reports on ABT shares. Finally, Zacks Investment Research cut shares of Abbott Laboratories from a "hold" rating to a "sell" rating in a report on Tuesday, March 28th. Finally, Cowen and Company reiterated an "outperform" rating and set a $48.00 target price on shares of Abbott Laboratories in a research note on Saturday, April 22nd. Boston Family Office holds 0.52% in Abbott Laboratories (NYSE:ABT) or 104,746 shares.
Among 5 analysts covering YPF SA (NYSE:YPF), 3 have Buy rating, 1 Sell and 1 Hold. Abbott Laboratories presently has an average rating of "Buy" and a consensus target price of $48.73. The stock of Abbott Laboratories (NYSE:ABT) has "Outperform" rating given on Friday, January 29 by RBC Capital Markets. Following the sale, the insider now owns 63,910 shares in the company, valued at $2,877,228.20. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Kinder Morgan Inc (KMI) Shares Bought by Private Bank & Trust Co
The institutional investors in our partner's database now possess: 1.22 billion shares, up from 1.18 billion shares in 2016Q3. News stories about Kinder Morgan (NYSE: KMI ) have trended somewhat positive on Sunday, according to AlphaOne Sentiment.
On 2/23/2017 Robert E Funck, VP, sold 25,500 with an average share price of $45.50 per share and the total transaction amounting to $1,160,250.00. Following the completion of the transaction, the vice president now owns 117,579 shares in the company, valued at approximately $5,349,844.50.
- Amazon Echo devices are getting better at recognizing wake words
- Nadal dominates Djokovic in Madrid Open semifinal
- EU restores preferential tax concessions to Sri Lanka
- Empire State Realty Trust, Inc. (NYSE:ESRT): Are Traders Shorting This Stock?
- Spend more, tax the rich: UK's Labour stakes election turf
- UN Security Council condemns North Korea missiles tests
- NHS cyberattack: Trusts were told about security patch last month
- Cyber Security James Clapper on Trump: US institutions are "under assault"
- WannaCry explained: What is WannaCry ransomware and how does it work?
- Chelsea can make Premier League history on Sunday